Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Centessa Pharmaceuticals (CNTA) Leases (2023 - 2026)

Centessa Pharmaceuticals has reported Leases over the past 3 years, most recently at $10.0 million for Q4 2025.

  • Quarterly Leases fell 8.77% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, down 8.77% year-over-year, with the annual reading at $10.0 million for FY2025, 8.77% down from the prior year.
  • Leases was $10.0 million for Q4 2025 at Centessa Pharmaceuticals, down from $10.3 million in the prior quarter.
  • Over five years, Leases peaked at $12.3 million in Q2 2023 and troughed at $10.0 million in Q4 2025.
  • The 3-year median for Leases is $11.4 million (2024), against an average of $11.3 million.
  • Year-over-year, Leases dropped 4.65% in 2024 and then dropped 8.77% in 2025.
  • A 3-year view of Leases shows it stood at $11.9 million in 2023, then decreased by 7.56% to $11.0 million in 2024, then dropped by 8.77% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Leases are $10.0 million (Q4 2025), $10.3 million (Q3 2025), and $10.5 million (Q2 2025).